{"id":20536,"date":"2025-03-21T19:20:20","date_gmt":"2025-03-21T12:20:20","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=20536"},"modified":"2025-03-21T19:20:20","modified_gmt":"2025-03-21T12:20:20","slug":"brii-biosciences-provides-corporate-update-and-reports-full-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=20536","title":{"rendered":"Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b<\/span> Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure<\/i><\/p>\n

Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio’s HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations<\/i><\/p>\n

4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30<\/span>)<\/i><\/p>\n

Strong Cash Reserves of US$335.7 Million<\/span> to Propel Operations into 2028<\/i><\/p>\n

Actively Seeking Partnership Opportunities for Non-HBV Programs<\/i><\/p>\n

Conference Call (English Session) Scheduled for March 31<\/span> at 8:30 PM<\/span> HKT \/ 8:30 AM ET<\/span><\/i><\/p>\n

DURHAM, N.C.\u00a0and BEIJING, China<\/span><\/span>, March 21, 2025<\/span><\/span> \/PRNewswire\/ — Brii Biosciences Limited<\/a>\u00a0(“Brii Bio<\/span>,” or the “Company,” stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024<\/span>.<\/p>\n

\n<\/div>\n

In 2024, Brii Bio<\/span> advanced its core hepatitis B virus (HBV) functional cure program, gaining <\/i>valuable data from ongoing Phase 2\u00a0trials that support its goal of achieving higher functional cure rates for patients through combined immunomodulation and surface antigen reduction approaches. These data support BRII-179 (a recombinant protein-based HBV immunotherapeutic) as a key differentiator through identifying patients who are potentially more susceptible to curative therapies. Two Phase 2b<\/span> studies, ENRICH and ENHANCE, are fully enrolled to confirm these important findings. End-of-treatment (EOT) data from its ENSURE study suggests a direct role of elebsiran (an HBV-targeting siRNA) in achieving a higher HBV functional cure rate. Elebsiran is currently being evaluated in multiple ongoing trials with Brii Bio’s<\/span> other assets,\u00a0including ongoing trials of tobevibart (a broadly neutralizing monoclonal antibody targeting HBV) run by Vir Biotechnology, Inc. (“Vir Biotechnology,” Nasdaq: VIR). Upcoming 2025 data readouts from these studies will guide Brii Bio’s<\/span> late-stage development and registration strategy. Brii Bio<\/span> remains well-funded with a cash position of US$335.7 million<\/span>, sufficient to support the Company through late-stage development plans for HBV functional cure.<\/p>\n

“The critical milestones we achieved in 2024 have strengthened our HBV portfolio of multiple mechanisms of action at both the clinical and strategic level,” stated Zhi Hong<\/span>, Ph.D., Chairman and Chief Executive Officer of Brii Bio<\/span>. “Data from multiple ongoing combination studies with our highly differentiated HBV assets continue to show that our multi-modal approach has the potential to produce higher functional cure rates across broader HBV patient groups. With the strategic acquisition of BRII-179 and data from three ongoing Phase 2b<\/span> studies throughout this year and next, we are creating multiple curative treatment options for patients with chronic HBV infection.”<\/p>\n

Clinical Development Update<\/u><\/b><\/p>\n

Brii Bio<\/span> is actively advancing its innovative product pipeline, with a primary focus on the late-stage clinical development of its flagship HBV program.<\/p>\n

HBV Program<\/b><\/i><\/p>\n

The Company is progressing multiple ongoing combination studies with its differentiated HBV candidates, including elebsiran, an HBV-targeting siRNA; BRII-179, a recombinant protein-based HBV immunotherapeutic. The Company’s partner, Vir Biotechnology, is also progressing multiple combination studies with elebsiran and\u00a0tobevibart, a broadly neutralizing monoclonal antibody targeting HBV surface antigen.<\/p>\n

By addressing HBV from these three distinct therapeutic perspectives in varying combinations with each other, Brii Bio<\/span> aims to determine the best curative regimens to address different population subsets and the most efficient regulatory path to approval. Upcoming pivotal data sets from the Company’s ongoing ENRICH (BRII-179 in priming HBV-specific immunity and enriching patients with competent immunity) and ENSURE (elebsiran in combination with PEG-IFN\u03b1 versus PEG-IFN\u03b1 alone) studies are expected throughout 2025-2026 and will further inform late-stage studies as Brii Bio<\/span> advances toward determining HBV functional cure.<\/p>\n